You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 2, 2024

Claims for Patent: 11,213,504

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,213,504

Title:	Stable pharmaceutical composition and methods of using same
Abstract:	The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
Inventor(s):	Manku; Mehar (Birmingham, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	17/137,713
Patent Claims:	1. A method of reducing triglyceride levels in a subject on statin therapy and having atrial fibrillation or atrial flutter and triglyceride levels of about 500 mg/dL to about 2500 mg/dL, the method comprising administering to the subject about 4 g of ethyl eicosapentaenoate per day. 2. The method of claim 1, wherein the subject has triglyceride levels about 750 mg/dL to about 2500 mg/dL. 3. The method of claim 1, wherein the subject has LDL-C levels of about 40 mg/dL to about 100 mg/dL. 4. The method of claim 1, wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition and the ethyl eicosapentaenoate comprises at least about 96 wt.% of all omega-3 fatty acids in the pharmaceutical composition. 5. The method of claim 4, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 6. The method of claim 1, wherein the subject is administered the ethyl eicosapentaenoate for a period of at least about 2 years. 7. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 5% after administration of the ethyl eicosapentaenoate. 8. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 10% after administration of the ethyl eicosapentaenoate. 9. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 15% after administration of the ethyl eicosapentaenoate. 10. The method of claim 1, wherein the subject exhibits a reduction in triglyceride levels of at least about 20% after administration of the ethyl eicosapentaenoate. 11. The method of claim 1, wherein the subject exhibits substantially no increase in an incidence of atrial fibrillation or atrial flutter after administration of the ethyl eicosapentaenoate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.